Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. by Alunni-Fabbroni, Marianna et al.
Alunni‑Fabbroni et al. J Transl Med          (2019) 17:328  
https://doi.org/10.1186/s12967‑019‑2079‑9
RESEARCH
Circulating DNA as prognostic biomarker 
in patients with advanced hepatocellular 
carcinoma: a translational exploratory study 
from the SORAMIC trial
Marianna Alunni‑Fabbroni1* , Kerstin Rönsch2, Thomas Huber1,3, Clemens C. Cyran1, Max Seidensticker1, 
Julia Mayerle4, Maciej Pech5, Bristi Basu6, Chris Verslype7, Julia Benckert8, Peter Malfertheiner4 and Jens Ricke1
Abstract 
Background: Liquid biopsy based on cell‑free DNA circulating in plasma has shown solid results as a non‑invasive 
biomarker. In the present study we evaluated the utility of circulating free DNA (cfDNA) and the sub‑type tumor DNA 
(ctDNA) in hepatocellular cancer (HCC) patients to assess therapy response and clinical outcome.
Methods: A cohort of 13 patients recruited in the context of the SORAMIC trial with unresectable, advanced HCC 
and different etiological and clinicopathological characteristics was included in this exploratory study. Plasma samples 
were collected between liver micro‑intervention and beginning of sorafenib‑based systemic therapy and then in 
correspondence of three additional follow‑ups. DNA was isolated from plasma and next generation sequencing (NGS) 
was performed on a panel of 597 selected cancer‑relevant genes.
Results: cfDNA levels showed a significant correlation with the presence of metastases and survival. In addition 
cfDNA kinetic over time revealed a trend with the clinical history of the patients, supporting its use as a biomarker 
to monitor therapy. NGS‑based analysis on ctDNA identified 28 variants, detectable in different combinations at the 
different time points. Among the variants, HNF1A, BAX and CYP2B6 genes showed the highest mutation frequency 
and a significant association with the patients’ clinicopathological characteristics, suggesting a possible role as driver 
genes in this specific clinical setting.
Conclusions: Taken together, the results support the prognostic value of cfDNA/ctDNA in advanced HCC patients 
with the potential to predict therapy response. These findings support the clinical utility of liquid biopsy in advanced 
HCC improving individualized therapy and possible earlier identification of treatment responders.
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Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer and the second leading cause of cancer-
related death globally, with a median survival of only 
7 months, if untreated [1–3]. Although cirrhosis, gener-
ally resulting from chronic inflammation and oxidative 
stress [4], is recognized as the most frequent risk factor, 
patients are often diagnosed with HCC in an already 
advanced phase, when treatment is limited and resec-
tion or transplantation are not any longer an option. This 
is in part due to the limited sensitivity and specificity of 
the standard diagnostic modalities of imaging and bio-
markers, such as serum alpha-fetoprotein (AFP) [5], in 
the detection of small tumors during surveillance of high 
risk populations. Advanced HCC often shows a poor out-
come, with very limited benefit from cytotoxic agents. 
Targeted therapy with the multi-tyrosine kinase inhibitor 
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sorafenib has been the mainstay of systemic treatment, 
nevertheless resulting in modest improvements in over-
all survival over placebo and often only in subgroups of 
patients [6]. Identification of early predictors of therapy 
response would be highly desirable in order to move 
quickly patients to more effective treatments.
Circulating cell-free DNA (cfDNA) is detectable in the 
plasma and serum of healthy individuals as consequence 
of cellular necrosis or apoptosis. Cancer patients show a 
higher amount of cfDNA since tumor cells divide faster 
than normal cells, and cfDNA is released in higher pro-
portion [7–9]. The fraction of cfDNA derived from the 
tumor is indicated as circulating tumor DNA (ctDNA) 
[10, 11]. In the last years, analysis of both cfDNA and 
ctDNA has gained considerable attention as novel blood 
biomarkers, since quantification and kinetic analysis of 
cfDNA [12, 13] and molecular profiling of ctDNA [14] 
have demonstrated both a predictive and prognostic 
value. Venipuncture, with capacity for serial sampling 
over time, may offer advantages over standard biopsy, 
avoiding complications from incisions and reflecting the 
genetic heterogeneity of the whole tumor. In addition, 
due to the short half-life of circulating DNA [15], genetic 
analysis may offer “real time” insights into the kinetic 
mutations arising during therapy. The prognostic value of 
cfDNA/ctDNA in early HCC has been previously shown 
[16, 17]. The aim of the present study was to evaluate if 
cfDNA quantification over time may be a valid monitor-
ing strategy to predict clinical outcome in advanced HCC 
patients in the context of the SORAMIC trial [18, 19], 
and whether molecular profiling of ctDNA may track the 
genetic evolution of the tumor during the combined sys-
temic and liver-directed micro-interventional treatment.
Methods
Patients and therapy
A total of 13 male patients (median age (years ± SD): 
68 ± 8.91, range 46–82) from the prospective rand-
omized multicenter phase II SORAMIC trial (EudraCT 
2009-012576-27, NCT01126645) were included in this 
exploratory study [18, 19]. Participants were recruited 
between 2011 and 2016 at different European study cent-
ers. Advanced, unresectable HCC patients received radi-
oembolization with Yttrium-90 (90Y-RE) in combination 
with systemic treatment with sorafenib (n = 10) or radiof-
requency ablation in combination with sorafenib (n = 2) 
or placebo (n = 1). Treatment efficacy was evaluated 
based on imaging and alfa-fetoprotein (AFP) [20, 21]. 
The median overall survival was 23.8 months (range 11.9 
– 41.4) and only two patients showed recurrence with a 
progression free survival of 22.3 and 26.8 months. Blood 
samples were collected at four different time points: 
after micro-interventional therapy and before starting 
the systemic therapy with sorafenib (T1), approximately 
8 weeks after beginning of systemic therapy (T2, median 
numbers of days between T1 and T2: 112), at first follow 
up (FU) (T3, median numbers of days between T1 and 
T3: 224) and at second FU (T4, median numbers of days 
between T1 and T4: 297). The SORAMIC trial design is 
given in Fig.  1, where the time points relative to blood 
collection are indicated. The study was approved by all 
the involved ethical boards and conducted in accordance 
with the Declaration of Helsinki [22]. Before entering the 
study, all patients gave their written informed consent.
DNA isolation, library preparation and next‑generation 
sequencing (NGS)
Peripheral blood (5  ml) was drawn in EDTA tubes (Bec-
ton–Dickinson, Heidelberg, Germany) and processed 
immediately (centrifugation 3000  rpm, 5  min, 4  °C) to 
collect plasma and buffy coats, which were aliquoted 
and stored at − 80  °C until further use. Plasma was used 
for extraction of cell-free DNA (cfDNA) and buffy coats 
were used for extraction of genomic DNA (gDNA). DNA 
extraction, quality control and NGS were performed at 
Eurofins Genomics GmbH (Konstanz, Germany). The 
quality and quantity of the extracted DNA was assessed via 
electropherograms and fluorometer concentration deter-
minations (for details, see Additional file 1: Figure S1). The 
extracted DNA was used for library preparation and sub-
sequent sequencing. A summary of the depth of coverage 
is shown in Additional file 2: Table S1.
The genes were selected according to their importance 
and in accordance with clinical guidelines such as the 
European Society for Medical Oncology (ESMO), the 
National Comprehensive Cancer Network (NCCN), and 
the College of American Pathologists (CAP).
NGS was performed on Illumina platform using the 
150 paired-end mode. The sequencing reads were qual-
ity checked and mapped to the human genome using 
BWA with default parameters [23]. After target process-
ing and alignment refinement, variants (single nucleotide 
variants, SNV; Insertions and deletions, InDel; and gene 
fusions according to Chimer DB 2.0 [24]) were discovered 
and annotated. To distinguish somatic from germline 
mutations, genomic DNA extracted from buffy coats 
was analyzed in parallel (Additional file 3: Table S2). The 
whole experimental workflow is schematically described 
in Fig. 2.
Statistical analysis
All statistical analyses were performed using IBM 
SPSS Statistics 21.0.0 (IBM Corporation, New York, 
N.Y.). Results for numerical data are given as median 
together with minimum and maximum of the sam-
ple (i.e. range). The correlation between tumor size and 
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cfDNA concentrations at different time points were ana-
lyzed using the Pearson’s correlation coefficient and cor-
responding significance test. cfDNA at different time 
points were compared between patient groups featuring 
different clinicopathological characteristics using the 
non-parametric Mann–Whitney U test. The association 
between variants at different time points and patients’ 
clinical characteristics was evaluated using the Fisher’s 
exact test. Overall survival (OS) was analyzed using the 
Kaplan–Meier method, and survival estimates in dif-
ferent groups were compared using the log-rank test. 
Patients were clustered in two groups corresponding to 
high and low cfDNA concentration (high cfDNA = over 
the median, low cfDNA = below the median). OS was 
calculated from the date of primary tumor diagnosis to 
the date of death or the date of the last clinical follow-
up. All tests were carried out two-sided. Due to the low 
sample size of n = 13 patients, no alpha adjustment was 
made. All statistical tests are interpreted at a significance 
level of alpha = 5% and according results are considered 
exploratory.
Results
Clinicopathological characteristics of the patients
Within the cohort chosen for this study, patients were 
divided in two subgroups: patients with an age below 
65, who did not present with liver cirrhosis at time of 
recruitment, did not report any past alcohol abuse and, 
based on the SORAMIC trial [19] results, responded 
better to therapies; and patients over 65, who presented 
with liver cirrhosis at time of recruitment, reported past 
alcohol abuse and responded worse to therapies. None 
of the patients were positive for Hepatitis B, only 1 was 
positive for Hepatitis C, and 4 presented non-alcoholic 
steatohepatitis (NASH). Three patients (33.3%, for n = 4 
the number of lesions was not available) presented with 
diffuse disease (> 20 lesions), while among the oth-
ers the median number of lesions was 2 (range 0–28) 
and the median size of the lesions was 49  mm (range 
8–160  mm). Three patients (23.0%) showed portal vein 
infiltration, all of them presented with a Child–Pugh A 
liver function, 46.1% (n = 6) of the patients were Barce-
lona Clinic Liver Cancer Staging (BCLC) C, while the 
remaining were A (n = 3, 23.0%) or B (n = 4, 30.7%). Four 
patients (30.7%) presented lymph node metastases and 
one of them (7.7%) also bone metastases. Two patients 
(66.6%) showed recurrence at 2 years FU. A summary of 
the clinicopathological characteristics of the patients is 
given in Table 1.
Correlation between cfDNA levels, patient’s 
clinicopathological characteristics and clinical outcome
cfDNA was isolated from plasma collected at the 4 time 
points (T1, T2, T3, and T4) during the SORAMIC trial. 
Nine of the 52 cfDNA samples (17.3%) were excluded 
from the subsequent analysis due to high genomic 
DNA contamination or because the concentration was 
below the threshold (Additional file  1: Figure S1). In 
the remaining samples, the amount of cfDNA at the 
different time points was ranging between 2.04  ng/
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Fig. 1 SORAMIC trial design. Indicated in red are the time points chosen for discovery of the variants. SNV, single nucleotide variant; InDel, insertion 
and deletion; R, randomization; TX, therapy; RFA, radiofrequency ablation; 90Y‑RE, 90Y‑radioembolization
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ml to 160.75 ng/ml with a median of 10.2 ng/ml at T1, 
15.3  ng/ml at T2, 9.3  ng/ml at T3 and 13.3  ng/ml at 
T4 (Table 2). We did not observe a significant correla-
tion between cfDNA concentration at T1 and tumor 
volume or between cfDNA concentrations at any time 
points and patient’s clinical characteristics (all p > 0.1) 
(data not shown). On the contrary, we did observe a 
difference between the concentrations of cfDNA in the 
presence or absence of metastases, which was signifi-
cant (p = 0.012) or borderline significant (p = 0.073) at 
T1 and T2, respectively (Fig.  3). The relative amount 
of cfDNA at the different time points was also evalu-
ated with respect to overall survival (OS). Patients 
were grouped according to high or low cfDNA levels 
with respect to the median values at the different time 
points. We found a borderline significance at the latest 
time points (T3, p = 0.057; T4, p = 0.095), suggesting 
that patients keeping high levels of plasmatic cfDNA 
while receiving systemic therapy might have a worse 
outcome (Fig. 4). On the contrary we did not find any 
association between cfDNA levels at earlier time points 
and OS (all p > 0.1). The fact the we found a borderline 
significance might be due to the low number of patients 
included in the analysis, therefore it will be neces-
sary to validate these preliminary results with a bigger 
cohort of patients.  
cfDNA in comparison to the conventional biomarker AFP
AFP is detectable in as many as 30% of HCC patients 
at time of diagnosis and usually remains low during 
the course of the disease, even with advanced HCC 
[20]. AFP > 400–500 ng/ml supports diagnosis of HCC 
[21]. At the considered time points, only 2 (15.4%) 
of the patients showed high AFP values (> 400  ng/
ml), 4 (30.8%) showed values between 20 and 400  ng/
ml and 7 (53.8%) showed values between 2 and 20 ng/
ml (Table  2). It has been already shown that cfDNA 
has clinical diagnostic relevance, reflecting therapy 
response [25]. We report here in more detail three 
vignettes of patients with evidence of disease pro-
gression, for which cfDNA offered earlier monitor-
ing value than conventional biomarkers such as AFP 
(Fig.  5). A concentration of 400  ng/ml was chosen as 
cut-off value. The first patient (patient B) entered in 
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Library Preparation
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Fig. 2 Schematic description of the experimental workflow. Peripheral blood was collected and processed to separate plasma from buffy coat 
containing white blood cells (WBC). Whole circulating DNA was extracted and used for library preparation. Next generation sequencing was 
performed on Illumina platform using the 150 paired‑end (PE) mode. To distinguish somatic from germline mutations, genomic DNA extracted 
from WBC was analyzed in parallel
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the trial with a diffuse disease in the liver and lymph 
nodes and bone metastases; he died after 38.6 months 
from enrolment in the SORAMIC trial. AFP concen-
tration was high (373  ng/ml) before starting sorafenib 
treatment; however it decreased very rapidly below 
50  ng/ml and remained low while assuming sorafenib, 
suggesting efficacy of treatment. On the contrary, we 
did not find a corresponding reduction in the cfDNA 
concentration which instead increased during time, 
suggesting the presence of progressive disease, as con-
firmed by CT imaging at follow up (Fig.  5a). The sec-
ond patient (patient E) entered in the study with lymph 
node metastases, portal vein infiltration and disease 
progression on treatment with an OS of 11.7  months 
from the beginning of therapy. At time points consid-
ered, AFP values were measured always below 50  ng/
ml; in contrast, cfDNA level, while showing a dras-
tic decrease immediately after the beginning of the 
therapy, increased rapidly between 6 and 8  months 
from the beginning of the therapy, reflecting the rapid 
progression of the disease and indicating a change in 
the response to sorafenib (Fig.  5b). The third patient 
(patient K) entered in the study presenting only one 
hepatic lesion and no evidence of metastases. AFP was 
always measured below 5 ng/ml at all time points, how-
ever cfDNA showed a steadily increase, predicting the 
progression of the disease. The patient finally relapsed 
and died shortly after (Fig. 5c). In conclusion, our data, 
in line with other reports, showed improved diagnostic 
sensitivity of cfDNA over AFP [24, 26], suggesting also 
in advanced HCC cfDNA as a biomarker for monitor-
ing therapy efficacy.
Somatic mutation analysis
Genomic profiling of ctDNA was undertaken at the 
different time points, with the screening of 597 can-
cer-relevant genes. Only those mutations proven to 
have clinical impact according to the ClinVar database 
(National Center for Biotechnology Information-NCBI) 
were further analyzed. In total 28 variants, including sin-
gle nucleotide variations (SNV) or insertions and dele-
tions (InDel) were discovered in our dataset, while no 
Table 2 Amount of  cfDNA (ng/ml) and  AFP (ng/ml) 
in plasma samples at the different time points
cfDNA median values are given for each patient at the four time points (last 
column) or for each time point for all patients (last row)
na, not available
Patients T1 T2 T3 T4 Median 
[cfDNA]cfDNA cfDNA cfDNA cfDNA
AFP AFP AFP AFP
A na 39.44 8.39 10.11 10.1
85.00 11.00 13.00 6.00
B 12.78 17.68 na 15.30 15.3
373.00 75.00 33.00 45.00
C 4.35 7.34 2.72 3.40 3.9
2.00 3.00 3.00 3.00
D 2.81 14.96 4.18 9.07 6.6
4.00 3.00 9.00 16.00
E 30.63 15.30 17.20 38.62 23.9
3.00 3.00 10.00 42.10
F 28.33 57.12 30.60 14.73 29.5
2.00 4.00 na 4.00
G 10.20 11.90 11.56 20.94 11.7
4.00 6.00 8.00 4.00
H 1.81 5.64 9.38 11.02 7.5
13.00 19.00 30.00 72.00
I 30.37 24.28 7.41 13.33 18.8
1681.00 1685.00 991.00 967.00
J 7.96 na 12.60 160.75 12.6
6154.00 2410.00 8732.00 3855.00
K 2.04 4.42 7.28 9.25 5.8
4.00 3.00 3.00 3.00
L 20.26 16.68 16.68 16.68 16.8
7.00 5.00 6.00 7.00
M na na na 8.98 8.98
9.00 4.00 4.00 6.00
Median [cfDNA] 10.2 15.3 9.3 13.3
Fig. 3 cfDNA concentrations at different time points and presence of 
metastases. The analysis shows that patients presenting metastases 
when recruited in the trial, had still a significant higher amount of 
plasmatic cfDNA in the timeframe between micro‑interventional 
therapy and the beginning of sorafenib‑based systemic therapy (T1, 
p = 0.012). Borderline significance (p = 0.073) was found after the 
beginning of systemic therapy (T2), while no significant difference 
was found at the two later time points. Comparison was performed 
using the Mann–Whitney U test (* ≤ 0.05)
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gene fusion was identified (Fig. 6). All patients showed at 
least one variant (median = 6 variants per patient, range 
3–16), however patterns varied between patients. Vari-
ants were found in genes involved in DNA repair, mul-
tidrug resistance, cell cycle control, signal transduction, 
transcription control, chromatin structure, apoptosis and 
DNA methylation (Table 3). We detected somatic muta-
tions in recognized HCC driver genes such as CTNNB1 
and TP53, however at very low frequency. Over the 28 
variants, three genes were showing the highest mutation 
allele frequency (MAF): HNF1A (n = 12, 92.3%), BAX 
(n = 9, 69.2%) and CYB2B6 (n = 6, 46.1%). We observed 
that in a high percentage of genes (n = 19, 68%) variants 
were found mainly after the beginning of sorafenib treat-
ment, suggesting a possible clonal selection induced by 
the therapy itself. Nevertheless, a different kinetic was 
also observed. For example, in the case of HNF1A, 50% 
of the patients showed the variant already before start-
ing to assume sorafenib. At T2, only one patient was still 
positive, suggesting a good therapy response. However at 
T3 the variant was showing a MAF of 82% (n = 9), a find-
ing which could suggest a clonal expansion of cells not 
responsive any longer to sorafenib. 
Association between variants, patient’s clinicopathological 
characteristics and overall survival
A possible association between the genetic variants and 
the patient’s clinicopathological characteristics was also 
evaluated. Due to the little size of the cohort, patients were 
clustered into those with variants identified only at early 
time points (T1 and T2) and those with variants identi-
fied only at later time points (T3 and T4). We measured 
a significant association between the BAX variant and 
portal vein invasion (p = 0.014) and between the HNF1A 
variant and liver cirrhosis (p = 0.032). For both genes, the 
significance was found only at the earlier time points. On 
the contrary, CYP2B showed to be significantly (p = 0.005) 
Fig. 4 Survival plots for HCC patients grouped according to the amount of cfDNA at the different time points. Patients’ total population was 
grouped according to the corresponding cfDNA concentration with respect to the median value found at each time point. Higher cfDNA 
concentration at later time points (T3 and T4) was showing a trend with a shorter OS (p = 0.057 and p = 0.095) while no association (p > 0.1) was 
found and earlier time points (T1 and T2). High and low cfDNA levels were defined as being above or below the median values at the different time 
points. OS was analyzed using the Kaplan–Meier method and survival estimates in the different groups were compared using the log‑rank test
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a
b
c
Fig. 5 Comparison between cfDNA and AFP levels in three cases corresponding to patients showing different clinical characteristics. Panels a, b 
and c represent the described clinical cases of patients B, E and K, respectively
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associated to BCLC grading only at the later time points. 
No further correlations were found (all p > 1.0) (Table 4).
We further evaluated the prognostic value of the 
genetic variants with respect to OS. Patients carrying 
the CYP2B6 variant in the time frame T1–T2 showed a 
worse OS (p = 0.013). On the contrary, when the same 
variant was detected at later time points, no signifi-
cant correlation was found (p = 0.360) (Fig. 7). No other 
genetic variant showed any correlation with the clinical 
outcome at any of the time points considered (all p > 0.1).
Fig. 6 Heatmaps showing the variants discovered in the two subgroups of patients (A–E: below 65, no liver cirrhosis, no past alcohol abuse and 
better response to therapies; F–M: over 65, with liver cirrhosis, past alcohol abuse and worse response to therapies) at the different time points. In 
(a) and in (b) SNV and InDel with relative mutation frequencies are reported, respectively
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Discussion
HCC is a heterogeneous pathology, involving multi-
ple somatic genomic alterations responsible for differ-
ent degrees of tumor differentiation and related clinical 
outcomes.
TP53 and CTNNB1 are the two most frequent muta-
tions although other driver mutations have been identi-
fied [27]. Genomic analysis, based on liver biopsy, allows 
the molecular subtyping of HCC and opens the door 
to select and adapt therapies to the individual patient’s 
needs. Apart from being associated to a higher risk for 
the patient, tissue biopsy presents nevertheless some 
limitations: first, the genetic heterogeneity in tumor dif-
ferentiation cannot be assessed by a single site sampling; 
second, the histopathological assessment of vascular 
invasion requires large biopsies; third, being highly inva-
sive, biopsy is usually performed only once during the 
whole therapy. Liquid biopsy is independent of these 
limitations and shows predictive and prognostic value 
in several types of cancer including HCC [12, 13, 28]. 
cfDNA quantitative changes have been mainly linked 
to tumor’s burden and therapeutic efficacy [26], while 
ctDNA qualitative changes can detect genetic variations 
in the tumor as a whole [16, 29].
In this exploratory study we investigated the prognos-
tic value of cfDNA/ctDNA isolated from advanced HCC 
patients over multiple time points in the context of the 
SORAMIC trial. We observed that the amount of cfDNA 
measured immediately after micro-intervention signifi-
cantly correlated with the presence of distant metastases, 
supporting also in this clinical context a diagnostic value 
Table 3 List of  variants grouped according to  gene 
function
Gene 
group
Location AA Codon Patients (%)
DNA repair
 ATM chr11:108121426 – c.1236‑
2A>T
2 (15.4)
 BLM chr15:91304138 p.N515fs
na
c.1544delA
c.*468delA
1 (7.7)
 BRCA2 chr13:32954022 p.T18fs
p.T3033fs
c.52insA
c.9097insA
1 (7.7)
 ERCC5 chr13:103524611 p.K150fs
p.K917fs
c.450delA
c.2751delA
5 (38.4)
 MSH6 chr2:48030639 p.F56fs
p.F1088fs
–
p.F958fs
p.F786fs
c.165delC
c.3261delC
c.*2608delC
c.2871delC
c.2355delC
6 (46.1)
 RAD50 chr5:131931451 p.K722fs
–
–
p.?661fs
c.2165delA
c.*1791delA
c.*351delA
c.1982delA
4 (30.8)
 WRN chr8:30915970 p.K5fs c.15delA 2 (15.4)
Multidrug resistance/xenobiotic metabolism
 ABCB1 chr7:87160618 p.S893A
p.S829A
c.2677T>G
c.2485T>G
3 (23.0)
 CYP2B6 chr19:41515263 p.K262R c.785A>G 6 (46.1)
 CYP2C9 chr10:96702047 p.R144C c.430C>T 1 (7.7)
 CYP2D6 chr22:42524994 p.P34S
p.P12S
c.100C>T
c.34C>T
2 (15.4)
 GSTP1 chr11:67352689 –
p.I105V
c.*137A>G
c.313A>G
2 (15.4)
 SLCO1B1 chr12:21331549 p.V174A c.521T>C 2 (15.4)
Cell cycle control/proliferation
 CTNNB1 chr3:41266098 p.D32V
p.D25V
c.95A>T
c.74A>T
1 (7.75)
 FGFR2 chr10:123274794 p.Y261C
p.Y147C
p.Y287C
p.Y263C
p.Y286C
p.Y375C
p.Y376C
p.Y377C
p.Y260C
–
c.782A>G
c.440A>G
c.860A>G
c.788A>G
c.857A>G
c.1124A>G
c.1127A>G
c.1130A>G
c.779A>G
c.*171A>G
1 (7.75)
 FGFR4 chr5:176520243 p.G23R
p.G388R
c.67G>A
c.1162G>A
1 (7.75)
 TP53 chr17:7579447 p.G254D
p.G113D
p.G206D
p.G152D
p.G86D
p.G234D
c.374G>A
c.338G>A
c.617G>A
c.455G>A
c.257G>A
c.701G>A
1 (7.75)
 TP53* chr17:7579407 p.A86fs
p.A47fs
c.257del279
c.140del162
1 (7.75)
Signal transduction signalling
 PIK3CA chr3:178952085 p.H1047R c.3140A>G 1 (7.75)
 PIK3CA* chr3:178952085 p.H1047L c.3140A>T 1 (7.75)
 SOS1 chr2:39249927 p.S548R c.1642A>C 1 (7.75)
Table 3 (continued)
Gene 
group
Location AA Codon Patients (%)
Chromatin structure
 ASXL1 chr20:31022441 p.G641fs
p.G646fs
c.1919insG
c.1934insG
3 (23.0)
Liver transcription factor
 HNF1A chr12:121432114 p.P291fs
p.G226fs
–
c.864delG
c.677delG
c.*304delG
12 (92.3)
Apoptosis
 BAX chr19:49458970 p.E41fs
p.R24fs
p.E24fs
c.121insG
c.69insG
c.70insG
9 (69.2)
DNA methylation
 DNMT3A chr2:25457242 –
p.R693H
p.R659H
p.R882H
c.*498G>A
c.2078G>A
c.1976G>A
c.2645G>A
2 (15.4)
Chromosome location, amino acid (AA) change and codon change are indicated
(na, not available)
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of cfDNA to unravel secondary lesions, as showed in other 
tumor types [25, 30, 31]. In addition, patients with post-
operative high levels of cfDNA had a shorter OS. Inter-
estingly, this holds true only at the later time points, after 
several weeks of sorafenib treatment, suggesting that also 
in advanced HCC cfDNA can support in monitoring ther-
apy response. This finding is relevant when considering 
the use of other biomarkers such as AFP [32, 33] whose 
prognostic value is still under debate [34, 35]. Among the 
patients enrolled in this study, only two patients had, over 
the considered time points, AFP concentrations higher 
than the assigned cut-off value of 400 ng/ml. On the con-
trary, quantitative analysis of post-operative cfDNA was 
always feasible and showed a trend with the clinical his-
tory of the patients, supporting the use of cfDNA to mon-
itor therapy response also in advanced HCC.
NGS analysis showed that all 13 patients presented 
SNV and/or InDel variants in a total of 28 genes, with 
6 as the median number of variants per patient. We 
never found two patients with an identical profile, sup-
porting the concept that HCC is a highly heterogeneous 
disease. Interestingly, only in few cases we detected the 
hotspot variants normally associated to HCC as those 
in TP53 or CTNNB1. We cannot exclude that this result 
is due to the low number of patients included in the 
study, therefore a validation study with a larger cohort 
will be necessary. However, these driver mutations are 
usually associated to specific etiological characteristics, 
not present in our patients’ group, such as HBV infec-
tion, dietary exposure to aflatoxin B1, or are per se very 
rare events [36]. The absence of these variants could be 
therefore associated to the clinical characteristics of the 
patients. In addition, in a multimodal meta-analysis run 
over 1494 HCC samples, it has been shown that other 
driver mutations, less frequent nevertheless still clini-
cally significant, can be identified [37]. From the 28 vari-
ants, we identified in particular 3 genes displaying high 
MAFs. CYP2B6 (mutated in 46.1% of the patients at least 
at one time point) belongs to the Cytochrome P450 class 
of enzymes which are important catalysts among all 
metabolizing enzymes. The isoform CYP2B6, expressed 
mainly in the liver, is highly polymorphic [38] (with the 
haplotype CYP2B6*6 found in the Caucasian population 
in up to 25% of the cases) and shows clinical relevance 
[38, 39]. However, there are contradictory results on 
the effect of the haplotype *6 (h*6). On one side it has 
been reported that patients carrying h*6 have a reduced 
amount of mRNA and protein [40], with an inferior 
response to specific treatments. On the other side, 
studies demonstrated that h*6 increase the enzymatic 
Table 4 Association between variant detection at different time points and patient’s clinicopathological characteristics
The analysis shows that there is a significant association between variants in CYP2B6, BAX and HNF1A and BCLS status (p = 0.005) portal vein invasion (p = 0.014) and 
absence of liver cirrhosis (p = 0.032), respectively. No association was found between any variant and presence of metastases or tumor size (all p > 1.0). Comparison 
was performed (for each time group separately) using the Fischer exact test
Variable Patients CYP2B6 (T1–T2) CYP2B6 (FU) BAX (T1–T2) BAX (FU) HNF1A (T1–T2) HNF1A (FU)
n 8 8 4 6 5 12
Portal vein invasion
 Yes 3 3 1 3 1 1 3
 No 10 5 7 1 5 4 9
 p 0.231 0.51 0.014* 1 1 1
BCLC
 A + B 7 4 7 1 2 2 7
 C 6 4 1 3 4 3 5
 p 1 0.005* 0.266 0.286 0.592 1
Metastases
 Yes 4 3 1 2 3 2 3
 No 9 5 7 2 3 3 9
 p 0.608 0.217 0.53 0.266 1 0.538
Cirrhosis
 Yes 8 6 6 3 4 1 7
 No 5 2 2 1 2 4 5
 p 0.293 0.293 0.608 1 0.032* 1
Tumor size (cm)
 < 5 6 2 4 2 2 2 6
 > 5 6 5 3 2 3 2 6
 p 0.242 1 1 1 1 1
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activity of CYP2B6 [41]. In our study, we found that 46% 
of the patients presented a CYP2B6 variant correspond-
ing to h*6 and that the detection of this variant at ear-
lier time points was significantly associated with a worse 
prognosis and a shorter OS. Since variants in enzymes 
involved in the metabolism can affect the response to 
specific drugs [42] and CYP450 and its haplotypes are 
involved in the metabolism of several drugs [39, 43], we 
can hypothesize that those patients presenting the vari-
ant h*6 responded worse to the therapy with sorafenib 
and therefore had a short OS.
BAX (mutated in 69.2% of the patients at least at one 
time point) belongs to the Bcl-2 gene family of pro-
apoptotic proteins [44]. Inactivation of BAX might be 
a mechanism to escape cell death, providing a survival 
advantage to the tumor. In colorectal cancer this particu-
lar frameshift mutation is indeed conferring an advantage 
to tumor progression, with p53-independent induction of 
apoptosis [45]. Sorafenib is a multikinase inhibitor with 
a strong anti-proliferative and anti-angiogenic effect 
on different cell types [46], displaying also a pro-apop-
totic effect [47]. BAX might play a role in cellular death 
induced by sorafenib, and the presence of this frameshift 
variant might predict a low therapy efficacy due to the 
inactivation of the pathway inducing apoptosis. Although 
we did not find any significant correlation between the 
presence of variants of BAX and OS, we unraveled a sig-
nificant correlation with portal vein invasion. Tumor cells 
able to overcome apoptosis display higher invasive char-
acteristics. The fact that 3 patients carrying this mutation 
are positive for portal vein infiltration might support the 
role of BAX in tumor invasion and the possible inefficacy 
of sorafenib in these patients. However at the moment 
this is just a hypothesis and further analysis will be neces-
sary to confirm it.
Finally, HNF1A showed the highest MAF, reaching 
92.3% over the whole cohort. HNF1A codes for a tran-
scription factor (HNF1α) which regulates liver differen-
tiation and development [48]. This transcription factor 
functions as a tumor suppressor [49] and its inactivation 
might play an important role in tumor development [50]. 
A recent work of Takashima et  al., demonstrated that 
the ectopic expression of HNF1α combined to other two 
transcription factors (HNF4a and FOXA3) successfully 
inhibited proliferation in a cellular model system [51]. 
If confirmed in other model system, HNF1A could be a 
novel target for combined therapy, especially when drug 
resistance is developed.
Moreover, while HNF1A inactivation is known to be 
frequent in hepatocellular adenoma, somatic mutations 
in this gene are relatively a rare event in HCC and very 
often bound to specific etiological characteristics such 
as absence of cirrhosis and viral infection [52]. In our 
cohort, none of the patients but one presented with viral 
infection and the presence of the variant showed a sig-
nificant negative association with cirrhosis. Although 
TP53 and CTBNN1 are the two most frequently mutated 
genes in HCC, there are other low frequency driver 
genes, such as HNF1A, which nevertheless are signifi-
cantly associated to patient’ survival. We can hypothesize 
that in the patient cohort selected for this study, HNF1A 
was a driver mutation. If confirmed in a larger number of 
patients, HNF1A could represent a novel target for per-
sonalized therapy.
A remarkable result we observed was the dynamic 
change of the mutation status over time. With respect 
to each gene taken individually, in the time frame 
between T1 and T4 we identified 6 categories of patients, 
showing: always the wildtype gene (WT); always the 
mutated gene (M); a single shift WT → M; a single shift 
M → WT; a double shift WT → M → WT; a double 
Fig. 7 Survival plots for HCC patients carrying the CP2B6 variant. 
Patients were grouped according to the time points (T1–T2, a; T3–T4, 
b). Patients carrying the variant at T1–T2, showed a worse survival 
with respect to those patients carrying the variant at T3–T4. OS was 
analyzed using the Kaplan–Meier method and survival estimates in 
the different groups were compared using the log‑rank test
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shift M → WT → M. With the small number of patients 
included in the study, for the moment we can only specu-
late that these changes are mirroring clonal heteroge-
neity found in the primary tumors [53, 54], evidenced 
because the analysis was done by liquid biopsy. It is rea-
sonable to speculate that the shift WT → M might take 
place because the mutated clones are more resistant to 
therapy; therefore post-treatment samples are enriched 
with ctDNA carrying the mutation. These clones possibly 
develop spontaneously and the mutation they carry con-
fers a selective advantage to cells. On the contrary, the 
shift M → WT might be observed because the mutated 
clones are more sensitive to therapy, which possibly 
could slow down their proliferation, while WT clones 
divide and expand faster. In the latter case we cannot 
exclude that ctDNA carrying the mutation is still present, 
however in this case the corresponding MAF is under 
the NGS detection threshold. Dynamic changes in clonal 
expansion during therapy are a known event [55], also 
strongly suggested by our data. Due to the limited num-
ber of samples, we cannot provide here anything more 
than a hypothesis. However it will be surely interesting 
to pursue in this direction, enlarging the number of cases 
and validating these preliminary results.
Conclusions
A validation study with a larger cohort and the inclu-
sion of appropriate control groups will be necessary 
to confirm these preliminary results and to support 
their clinical value. Also a more detailed comparison 
between patients receiving ablation or radio-embo-
lization should be considered to understand if differ-
ent procedures possible with the micro-interventional 
therapy might induce the accumulation of alterna-
tive genetic mutations. However, from the results 
obtained from this exploratory study we can conclude 
that also in advanced HCC after micro-intervention 
cfDNA quantification is feasible, can support standard 
imaging analysis for the early detection of metastatic 
lesions and is showing a prognostic value with respect 
to OS. In addition, interrogating ctDNA for genetic 
variants can reduce understaging of clonal selection as 
a consequence of systemic therapy, in the potential to 
improve longitudinal monitoring of therapy efficacy. 
HCC is a highly heterogeneous tumor type; it would 
be therefore an advantage to tailor therapy accord-
ing to the intrinsic genetic characteristics. None of 
the patients included in this study showed an identi-
cal genomic profile, supporting the concept that also 
in advanced HCC personalized therapy is necessary to 
improve clinical outcome. A rapid adaption of therapy 
in concomitance to variant appearance and therefore a 
more efficient treatment might be particularly impor-
tant for patients already in an advanced stage of the 
disease and therefore with a relative short overall sur-
vival expectancy.
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